

Alzheimer's Update to Chapter 112 December 2025

NOW IS
THE MOMENT
TO DO MORE,
NOT LESS, IN THE
FIGHT AGAINST
ALZHEIMER'S



Laura Moore

December 15, 2025

CONTRIBUTIONS REPORT

NARFE Alzheimer's Research Fund

The Alzheimer's Association NARFE Page reports that NARFE has accomplished and exceeded its 2025 \$16 Million goal, reporting that \$16.6 Million has been received and distributed to NARFE Research grants. The year end goal for 2026 is \$17 Million. Reports, so far, on the POTUS 47 Administration impacts to the National Institute of Health and research programs are still very much wait and see.

The Chapter has collected \$100 to send forward to NARFE Alzheimer's Research Fund. Thank you to participants in the Holiday party raffle for \$70. The balance has been collected through the Autumn from Chapter meetings.

A special thanks also to the long-time, personal contributions of money and *time* as she will be presented with a certification of appreciation in recognition of her service to the NARFE Alzheimer program at the January 14, 2026 Chapter 0112 meeting.

AROUND THE ALZHEIMER'S COMMUNITY

Did you know there is an Alzheimer's Store? Products they carry focus on aids for fighting mental decline, stress release toys and safety items like GPS trackers and door alarms for wandering loved ones. Visit the store at www.alzstore.com

Participate in Research

Discover the new and improved TrialMatch experience

The Alzheimer's Association endorses TrialMatch which has transitioned to a new platform, making it easier than ever to find research opportunities that matter to you. Participate in this updated experience in three easy steps:

- Visit TrialMatch. Begin your journey by signing up on the dedicated TrialMatch platform. Assistance is available by phone at 800.272.3900 or email TrialMatch@alz.org.
- Answer 10 simple questions. Share some basic information about yourself or the person you're helping. This helps TrialMatch personalize your study matches across areas like treatment, care and prevention. Your information will remain completely confidential unless you choose to share it with a study team.
- Review your study matches. Explore the studies that may be a good fit. Participation is entirely voluntary, and you can reach out to researchers directly or let them know you're interested in learning more.

Guidance is offered for every step of your participation with TrialMatch. Help shape the next breakthrough with TrialMatch.

CONGRESSIONAL REPORT

During the 118th Congress, Sen. Catherine Cortez Masto (D-NV) played a key role in introducing the bipartisan BOLD Reauthorization Act (P.L. 118-142), which reauthorizes the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer's Act (P.L. 115-406) and empowers public health departments to implement effective dementia interventions. The bill passed Congress unanimously and was signed into law, thanks in large part to Sen. Cortez Masto's leadership. Sen. Cortez Masto was an original sponsor of the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer's Act (P.L.115-406), which was signed into law in 2018.

During the 119th Congress, Sen. Cortez Masto has been a fierce advocate to ensure funding has been secured, advocating for Alzheimer's research and programs at the CDC. As a

member of the Senate Committee on Finance, Sen. Catherine Cortez Masto has been a strong supporter of the Alzheimer's Association and AIM's federal priorities, including the Comprehensive Care for Alzheimer's Act, the Improving HOPE for Alzheimer's Act and the Palliative Care and Hospice Education and Training Act. Just last month, Sen. Cortez Masto helped introduce the bipartisan Alzheimer's Screening and Prevention (ASAP) Act ([H.R. 6130/S. 3267](#)).

On December 4, 2025 Joanne Pike, DrPH, President and CEO of the Alzheimer's Association, joined Senator Susan Collins (R-ME) and *Punchbowl News* to talk about the fight to end Alzheimer's and advancements being made in dementia research. [Learn more](#).

During the event, Dr. Pike and Sen. Collins discussed the newly-introduced [Alzheimer's Screening and Prevention \(ASAP\) Act \(H.R. 6130/S. 3267\)](#). This bipartisan legislation would create a pathway for Medicare coverage of Food and Drug Administration (FDA)-approved and cleared biomarker screening tests, accelerating access to blood biomarker tests and earlier detection of Alzheimer's and other dementia. A biomarker diagnosis helps individuals plan for the future, join clinical trials, and possibly access treatments sooner. **Urge your member of Congress to help [advance this important legislation TODAY!](#)**

You can also urge your members of Congress to prioritize continued investments in Alzheimer's research and the public health infrastructure. **Take action here, [TODAY!](#)**

Advocates are continuing to grow support for the [Accelerating Access to Dementia & Alzheimer's Provider Training \(AADAPT\) Act \(H.R. 3747\)](#). Building upon existing video-conference-based education programs, this legislation aims to empower primary care providers to better diagnose Alzheimer's and other dementia and deliver high-quality, person-centered care in community-based settings by addressing the knowledge gaps and workforce capacity issues primary care providers often face. **You can help by taking action [today!](#)**

December 3, the Senate Special Committee on Aging held a hearing on "Aging in Place: The Impact of Community during the Holidays." The Alzheimer's Association and AIM submitted a [statement for the record](#) highlighting the importance of social connection, home- and community-based services, and long-term care in helping people with Alzheimer's and

other dementia remain in their homes as long as possible.

On November 5, Alzheimer's Association and AIM volunteer, Erick Montealegre of Florida, [testified](#) before the Senate Special Committee on Aging. Erick, a dedicated caregiver for his father living with mild cognitive impairment, shared his personal story to highlight the importance of programs supported by the Older Americans Act (OAA). This hearing was a key opportunity to demonstrate how the OAA supports families impacted by Alzheimer's and other dementias, and reinforces our advocacy for its reauthorization. Read AIM's OAA letter of support [here](#) and statement for the record [here](#).

SEPARATE BUT EQUAL?

In November, Texas voters [overwhelmingly approved Proposition 14](#), authorizing a \$3 billion investment to create the Dementia Prevention and Research Institute of Texas (DPRIT), the largest state-funded dementia research and prevention initiative in the nation. This is more than a historic investment; it's a commitment to a future where pioneering research benefits everyone.

Unfortunately, [a lawsuit now seeks to block DPRIT's implementation](#). This challenge undermines the will of nearly 70% of Texas voters who sent a clear message: Texas is ready to lead the way in scientific discovery. Every day without progress means more lives impacted, more caregivers stretched to the limit, and more missed opportunities for breakthroughs.

The Alzheimer's Association stands firmly with state leaders who championed this initiative and urges the courts to dismiss this lawsuit swiftly. Texans endorsed hope, innovation, and accountability when they voted for Proposition 14 — and we are committed to ensuring that promise is fulfilled for the more than half a million Texans living with dementia and millions of caregivers nationwide. Source: Alzheimers Impact Movement Weekly Report, Dec 14, 2025.

IN THE WORLD, BY COMPARISON

Compiled by ChatGPT

1. Global Coordination & Advocacy

Alzheimer's Disease International (ADI)

ADI is the global federation of Alzheimer's associations in over 100 countries, pushing for dementia research to be a public health priority worldwide. They publish the World Alzheimer Report (most recent 2025 edition emphasizes rehabilitation and care strategies).

World Health & Regional Partnerships

The Pan American Health Organization (PAHO/WHO) and ADI launched a regional awareness and stigma-reduction campaign in the Americas — part of broader global action recognizing dementia as a leading noncommunicable disease.

Davos Alzheimer's Collaborative

This global initiative partners public health systems and governments (e.g., Brazil, Japan, Scotland, Mexico, Jamaica) to implement biomarker-based early detection and technology-enabled care in routine practice, with WHO advising on technical standards.

Funding Pressures

ADI has warned that cuts to overseas development aid and global research funding could slow services and scientific progress, especially in low- and middle-income countries. [And low- and middle-income US states?]

2. Clinical Trials & Treatments Outside the U.S.

Regulatory and Access Differences

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved lecanemab for early Alzheimer's, a major antibody-based treatment, though the European Medicines Agency (EMA) initially gave a negative opinion but may reconsider.

Private Treatment Availability

In Europe, some clinics (e.g., in London) now offer lecanemab and donanemab commercially to private patients, reflecting both clinical demand and healthcare system gaps in public access.

Industry & Cross-Border Trials

Major global pharma collaborations continue: for example, the antibody therapy Leqembi® (co-developed by Japan's Eisai with Biogen) is being evaluated in real-world studies with international data.

3. Research & Scientific Collaborations

International Conferences & Knowledge Sharing

Major scientific meetings such as the ADPD 2025 Alzheimer's & Parkinson's disease conference in Vienna brought together researchers from 70+ countries to share insights across neurodegenerative diseases — aiming for cross-disease therapeutic advances.

Cross-Country Studies

Longitudinal and observational studies like the Czech Brain Ageing Study continue in Europe, generating valuable data on aging and dementia progression and complementing U.S.-led multicenter efforts.

Data Sharing Initiatives

Open data platforms such as the Global Alzheimer's Association Interactive Network (GAAIN) facilitate large-scale international access to clinical records and research findings, enabling broader collaboration.

—

4. Emerging Technologies & Research Trends

AI & Computational Research

AI and machine-learning are increasingly used to analyze complex Alzheimer's data, design better clinical trials, and mine biomarkers — efforts supported by global initiatives and special journal issues highlighting these innovations.

Novel Biological Approaches

In cross-continental scientific work, researchers from Spain and China reported a nanotechnology strategy that reversed Alzheimer-like pathology in mice by repairing the blood-brain barrier — a potentially transformative preclinical finding.

5. Challenges & Gaps in Global Research

Care & Equity Issues

Studies across regions (USA, Europe, Israel, China) show that many people with dementia lack access to basic care services, highlighting a gap between scientific advances and real-world outcomes.

Resource Disparities

While wealthier nations contribute robustly to research and trials, many low- and middle-income countries struggle with funding, infrastructure, and access — a concern flagged by international advocacy groups.

Summary

International Alzheimer's research is expanding rapidly beyond the U.S., driven by:

Global research networks and data sharing

Cross-national clinical trials and regulatory developments

NGO collaboration and health system partnerships

Advanced AI and biotechnological innovations

...but challenges remain in equitable access to new treatments, research funding in low

er-resource settings, and translating scientific breakthroughs into global health impact.
Source: ChatGPT

REFERENCES FOR YOUR PERSONAL USE

1. NARFE enews: alz.org/narfemembers or <https://alz.org/forms/narfe>
2. Alzheimer's Impact Movement: <https://alzimpact.org>
3. St Louis Chapter of the Alzheimer's Association phone: 314 801 0420
4. ChatGPT artificial intelligence engine

For any direct contributions you would like to make, **please make out your checks to NARFE ALZHEIMER'S RESEARCH** and include your Chapter Number -112 -on the notations line. Mail to Laura Moore, 2619 Heger Court, St Louis MO 63110 Mobile Phone: 314 3991122

